504 related articles for article (PubMed ID: 29481970)
21. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
[TBL] [Abstract][Full Text] [Related]
22. Emerging biologics in inflammatory bowel disease.
Chan HC; Ng SC
J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease.
Lutz M; Caldera F; Schroeder K; Gazis D; Crawford JM; Long MD; Barnes EL
Clin Transl Gastroenterol; 2023 Nov; 14(11):e00620. PubMed ID: 37450671
[TBL] [Abstract][Full Text] [Related]
24. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.
Goessens L; Colombel JF; Outtier A; Ferrante M; Sabino J; Judge C; Saeidi R; Rabbitt L; Armuzzi A; Domenech E; Michalopoulos G; Cremer A; García-Alonso FJ; Molnar T; Karmiris K; Gecse K; Van Oostrom J; Löwenberg M; Farkas K; Atreya R; Ribaldone DG; Selinger C; Hoentjen F; Bihin B; Sebastian S; ; Rahier JF
United European Gastroenterol J; 2021 Dec; 9(10):1136-1147. PubMed ID: 34694746
[TBL] [Abstract][Full Text] [Related]
26. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
27. Treatment of inflammatory bowel disease (IBD).
Pithadia AB; Jain S
Pharmacol Rep; 2011; 63(3):629-42. PubMed ID: 21857074
[TBL] [Abstract][Full Text] [Related]
28. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
Khan N; Asim H; Lichtenstein GR
Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
[TBL] [Abstract][Full Text] [Related]
29. Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
Ben-Horin S; Mao R; Chen M
BMC Gastroenterol; 2015 Dec; 15():178. PubMed ID: 26678147
[TBL] [Abstract][Full Text] [Related]
30. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
Ward MG; Irving PM; Sparrow MP
World J Gastroenterol; 2015 Oct; 21(40):11331-42. PubMed ID: 26525434
[TBL] [Abstract][Full Text] [Related]
31. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.
Adelzadeh L; Jourabchi N; Wu JJ
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):846-52. PubMed ID: 25081573
[TBL] [Abstract][Full Text] [Related]
32. [Safety and effectiveness of biologics in treating inflammatory bowel diseases in pregnancy].
Tursi A
Recenti Prog Med; 2010 Oct; 101(10):396-401. PubMed ID: 21137576
[TBL] [Abstract][Full Text] [Related]
33. Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease.
Xu YH; Zhu WM; Guo Z
World J Gastroenterol; 2022 Dec; 28(48):6888-6899. PubMed ID: 36632311
[TBL] [Abstract][Full Text] [Related]
34. Adalimumab for the treatment of inflammatory bowel disease.
Wasan SK; Kane SV
Expert Rev Gastroenterol Hepatol; 2011 Dec; 5(6):679-84. PubMed ID: 22017695
[TBL] [Abstract][Full Text] [Related]
35. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
[TBL] [Abstract][Full Text] [Related]
36. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
37. Adverse effects of biologics used for treating IBD.
Stallmach A; Hagel S; Bruns T
Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):167-82. PubMed ID: 20227030
[TBL] [Abstract][Full Text] [Related]
38. Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease.
Balderramo D
World J Gastroenterol; 2022 Dec; 28(47):6743-6751. PubMed ID: 36620336
[TBL] [Abstract][Full Text] [Related]
39. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
